[1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024,74:229-263.
|
[2] |
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46: 221-231.
|
[3] |
Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023,20:338-349.
|
[4] |
Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022,33:1005-1020.
|
[5] |
Sato T, Vries R G, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009,459:262-265.
|
[6] |
LeSavage BL, Suhar RA, Broguiere N, et al. Next-generation cancer organoids[J]. Nat Mater, 2022,21:143-159.
|
[7] |
Marx V. Closing in on cancer heterogeneity with organoids[J]. Nat Methods, 2024,21:551-554.
|
[8] |
Yan H, Chan AS, Lai FP, et al. Organoid cultures for cancer modeling[J]. Cell Stem Cell, 2023,30:917-937.
|
[9] |
McCracken KW, Catá EM, Crawford CM, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids[J]. Nature, 2014,516:400-404.
|
[10] |
Huang XZ, Pang MJ, Li JY, et al. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis[J]. Nat Commun, 2023,14:822. doi: 10.1038/s41467-023-36310-9.
|
[11] |
Koh V, Chakrabarti J, Torvund M, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids[J]. Cancer Lett, 2021,518:59-71.
|
[12] |
Yao L, Hou J, Wu X, et al. Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation[J]. Redox Biol, 2023,67:102923. doi:10.1016/j.redox.2023.102923.
|
[13] |
Zhao H, Cheng Y, Kalra A, et al. Generation and multiomic profiling of a TP53/CDKN2A double-knoc-kout gastroesophageal junction organoid model[J]. Sci Transl Med, 2022,14:eabq6146. doi:10.1126/scitranslmed.abq6146.
|
[14] |
Zhang F, Sahu V, Peng K, et al. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer[J]. Gut, 2024:gutjnl-2023-329686. doi: 10.1136/gutjnl-2023-329686.
|
[15] |
Arai J, Hayakawa Y, Tateno H, et al. Impaired glycosylation of gastric mucins drives gastric tumorigenesis and serves as a novel therapeutic target[J]. Gastroenterology, 2024. doi:10.1053/j.gastro.2024.03.037.
|
[16] |
Mircetic J, Camgöz A, Abohawya M, et al. CRISPR/Cas9 screen in gastric cancer patient-derived organoids reveals KDM1A-NDRG1 axis as a targetable vulnerability[J]. Small Methods, 2023,7:e2201605. doi:10.1002/smtd.202201605.
|
[17] |
Peng K, Zhang F, Wang Y, et al. Development of combination strategies for focal adhesion kinase inhibition in diffuse gastric cancer[J]. Clin Cancer Res, 2023,29:197-208.
|
[18] |
Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018,359:920-926.
|
[19] |
Zu M, Hao X, Ning J, et al. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing[J]. Biomed Pharmacother, 2023,163:114751. doi:10.1016/j.biopha.2023.114751.
|
[20] |
Schmäche T, Fohgrub J, Klimova A, et al. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold[J]. Mol Cancer, 2024,23:10. doi:10.1186/s12943-023-01919-3.
|
[21] |
Lin W, Zhang Y, Yang Y, et al. Anti-PD-1/Her2 bispecific antibody IBI315 enhances the treatment effect of Her2-positive gastric cancer through gasdermin B-cleavage induced pyroptosis[J]. Adv Sci (Weinh), 2023,10:e2303908. doi:10.1002/advs.202303908.
|
[22] |
Kwon JW, Oh JS, Seok SH, et al. Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency[J]. Mol Cancer, 2023,22:156. doi:10.1186/s12943-023-01857-0.
|
[23] |
Dao L, You Z, Lu L, et al. Modeling blood-brain barrier formation and cerebral cavernous malformations in human PSC-derived organoids[J]. Cell Stem Cell, 2024,31:818-833.
|
[24] |
Hwangbo H, Chae S, Kim W, et al. Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues[J]. Theranostics, 2024,14:33-55.
|
[25] |
Wu J, Li T, Guo M, et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue[J]. Cell Discov, 2024,10:45. doi:10.1038/s41421-024-00662-3.
|